Jonathan Violin - 02 Jun 2026 Form 4 Insider Report for CRESCENT BIOPHARMA, INC. (CBIO)

Reporting relationship: Director
Issuer ticker: CBIO
Reported as of: 02 Jun 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 03 Jun 2026, 19:48:33 UTC
Prior SEC filing: 22 May 2026
Source filing: View source filing
Reporting owner signature: /s/ Barbara Bispham, as attorney-in-fact for Jonathan Violin

Key filing fact

Jonathan Violin filed Form 4 for CRESCENT BIOPHARMA, INC. (CBIO) on 03 Jun 2026.

Key facts

This page summarizes Jonathan Violin's Form 4 filing for CRESCENT BIOPHARMA, INC. (CBIO).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 03 Jun 2026, 19:48.

Change

Previous filing in this sequence was filed on 22 May 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001730615 Primary reporting owner

Violin Jonathan

Relationship: Director
Address: C/O/ CRESCENT BIOPHARMA, INC., 300 FIFTH AVENUE, WALTHAM
Signature: /s/ Barbara Bispham, as attorney-in-fact for Jonathan Violin
Signature date: 03 Jun 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CBIO transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares: +11,050
Change %
Price: $0.000000^*
Shares after: 11,050
Date: 02 Jun 2026
Ownership: Direct
Underlying class: Ordinary Shares
Underlying amount: 11,050
Exercise price: $17.01
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

This option represents a right to purchase 11,050 of the Issuer's ordinary shares and vests in full on the earlier of (i) June 2, 2027 or (ii) the date of the Issuer's next annual meeting of shareholders, in each case, subject to the Reporting Person's continued service to the Issuer.